Tevogen Inc. Warrant financials
$0.0601−7.54%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$26.1M | -$53.6M |
| Net income | -$26.8M | -$10.3M |
| Net margin | — | — |
| Diluted EPS | $-8.08 | $-3.50 |
| EBITDA | -$25.6M | -$53.2M |
| Operating cash flow | -$12.3M | -$12.0M |
| Free cash flow | -$12.4M | -$12.0M |
| Diluted shares | 3.3M | 2.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $552.4K | $1.3M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $6.1M | $2.7M |
| Total assets | $4.4M | $3.5M |
| Total liabilities | $12.6M | $10.1M |
| Shareholders' equity | -$8.2M | -$6.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology